Finnish startup Proteins.1 unveils protein amplification platform for early disease detection

Proteins.1 has come out swinging with a familiar promise from the DNA world: PCR for proteins. The Espoo, Finland-based startup launched on April 16, 2026, with a platform it says can amplify protein signals at the single-molecule level, making ultra-early disease detection simpler and more scalable.

That matters because proteomics has long been stuck between sensitivity and usability. Proteins.1 says its system is enzyme-free, physics-based and built around cyclic signal amplification, with claims of up to 1,000-times better sensitivity than current gold-standard platforms. The company also says it can measure hundreds of biomarkers at once from just a few drops of blood, a combination that would be especially useful if the goal is to catch disease-related signals before symptoms appear.

The medical case is straightforward. Aalto University has noted that in diseases such as cancer and Alzheimer’s disease, relevant proteins can show up early but often at concentrations too low for standard blood tests to detect. That is the gap Proteins.1 is trying to close, and it is a big one. If the platform can really pull faint protein signals out of noisy biological samples without turning every assay into a specialist workflow, it could matter in research labs first and, later, in screening and clinical settings where speed and sensitivity are everything.

The company traces its technology back to work at VTT Technical Research Centre of Finland in 2018. Proteins.1 says it now holds granted US and Finnish patents, with additional international patent applications pending. It has also secured €4.7 million in pre-seed funding, led by Lifeline Ventures and Cloudberry Ventures, with in-kind backing from VTT and Business Finland. The startup says European Union breakthrough innovation funding helped validate the approach along the way.

Leadership is another clue to how seriously the company is taking the jump from lab concept to product. Proteins.1 was founded in July 2025 by CEO Prateek Singh, COO Harri Hallila and Tuan Nguyen. VTT says Singh has previously raised venture capital for microfluidics ventures and holds multiple patent families, while Hallila previously built and exited a regulated medical device company. That mix of deep-tech IP, medtech experience and financing muscle is exactly what a platform like this needs if it is going to survive contact with real samples and real workflows.

The broader Finnish context helps too. VTT says its spin-off companies accounted for 8.2% of all capital funding invested in Finnish startups between 2013 and 2022, a sign that the country’s research pipeline has already produced commercially credible companies. Proteins.1 is trying to add protein diagnostics to that list, and the bet is clear: if protein measurement can be made as routine as amplification-based DNA testing, early disease detection could get a lot less theoretical.